Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00508326 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00508326: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00508326 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00508326, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00508326
The ClinicalTrials.gov registry entry for NCT00508326 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT00508326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00508326 about?
NCT00508326 is a clinical study titled "Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement". The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
What is the current status of trial NCT00508326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2005-10. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00508326?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00508326?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.